Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
The research on BPC-157 (pentadecapeptide) consists primarily of preclinical animal studies, with limited human clinical trial data currently available.
Preclinical Animal Studies
Several rat studies have investigated BPC-157's protective effects across different physiological systems. A 2026 study examined BPC-157 as therapy following unilateral adrenalectomy in rats, exploring its cytoprotective potential. Another rat study investigated the peptide's protective effects in experimentally induced lower extremity ischemia-reperfusion injury, suggesting potential benefits for tissue protection during blood flow restoration.
Research has also explored BPC-157's effects on electrolyte disturbances in rats and its role in managing severe electrolyte imbalances. Additionally, studies have examined the peptide's interaction with the cholinergic system, investigating BPC-157 and hybrid analogs as acetylcholinesterase inhibitors.
Human Tissue Studies
One notable 2026 study examined BPC-157's vasorelaxant effects in human internal mammary artery tissue, investigating endothelium-dependent, nitric oxide-mediated mechanisms. This represents some of the limited research using human tissue samples.
Clinical Trials
Currently, there is one active Phase 2 clinical trial (NCT07437547) recruiting participants to study BPC-157 for acute hamstring muscle strain repair. This appears to be among the first controlled human studies of this peptide.
Research Limitations
The available evidence is heavily weighted toward animal studies, with minimal human clinical data. Several review papers discuss theoretical applications for tissue repair, pain management, and cytoprotection, but note significant biopharmaceutical challenges and development barriers that have limited translation to human medicine.
Note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.